Get the Stockscreener App
6.49
3.85%
-0.26
After Hours:
6.48
-0.010
-0.15%
Design Therapeutics Inc stock is traded at $6.49, with a volume of 202.78K.
It is down -3.85% in the last 24 hours and up +7.63% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
See More
Previous Close:
$6.75
Open:
$6.75
24h Volume:
202.78K
Relative Volume:
1.31
Market Cap:
$369.59M
Revenue:
-
Net Income/Loss:
$-66.86M
P/E Ratio:
-5.4083
EPS:
-1.2
Net Cash Flow:
$-58.82M
1W Performance:
+2.20%
1M Performance:
+7.63%
6M Performance:
+124.57%
1Y Performance:
+29.80%
1-Day Range:
$6.30
$6.79
1-Week Range:
$6.18
$7.22
52-Week Range:
$2.60
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
6.49 | 384.40M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
Does Design Therapeutics Inc. fit your quant trading modelIndex Update & Risk Controlled Daily Trade Plans - newser.com
Is it time to cut losses on Design Therapeutics Inc.Analyst Downgrade & Risk Controlled Daily Plans - newser.com
Published on: 2025-10-10 09:52:08 - newser.com
Leading vs lagging indicators on Design Therapeutics Inc. performanceJuly 2025 Intraday Action & Daily Entry Point Alerts - newser.com
Is Design Therapeutics Inc. a candidate for recovery playJuly 2025 EndofMonth & Accurate Entry/Exit Alerts - newser.com
Design Therapeutics Inc. stock volume spike explainedJuly 2025 Short Interest & AI Optimized Trade Strategies - newser.com
How Design Therapeutics Inc. stock reacts to global recession fears2025 Dividend Review & Technical Buy Zone Confirmation - newser.com
Why Design Therapeutics Inc. stock is in analyst buy zone2025 Technical Overview & Low Drawdown Trading Strategies - newser.com
Design Therapeutics (NASDAQ:DSGN) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Published on: 2025-10-09 02:15:05 - newser.com
Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025 - Yahoo Finance
Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Epidemiology, Regulatory Landscape, Ong - PharmiWeb.com
Is Design Therapeutics Inc a good long term investmentInstitutional Buying Trends & Low Entry Investment Plans - earlytimes.in
Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Epidemiology, Regulatory Landscape, Ongoing Clinical Trials, Market Dynamics, Patent AnalysisResearchAndMarkets.com - Business Wire
Design Therapeutics Inc. recovery potential after sell offFed Meeting & Real-Time Chart Pattern Alerts - newser.com
Should you hold or exit Design Therapeutics Inc. now2025 Technical Overview & Smart Investment Allocation Tips - newser.com
Top chart patterns to watch in Design Therapeutics Inc.2025 Price Targets & Free Verified High Yield Trade Plans - newser.com
RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Maintains Target Price $5 - 富途牛牛
Analyzing Design Therapeutics Inc. with multi timeframe chartsJuly 2025 Big Picture & Smart Allocation Stock Tips - newser.com
Risk adjusted return profile for Design Therapeutics Inc. analyzedEarnings Performance Report & Stepwise Entry and Exit Trade Signals - newser.com
Why Design Therapeutics Inc. stock is a must watch in 2025Trade Signal Summary & Smart Swing Trading Alerts - newser.com
Twist Bioscience Announces Publication in Science Examining Biosecurity Screening Practices in AI-assisted Protein Design - Business Wire
Vector Science & Therapeutics Appoints Tabitha Hendren as Director, Engineering and Design - PR Newswire Canada
Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Bausch + Lomb, Santen Pharmaceutical, and Trefoil Therapeutics, Actively Shaping the Competitive Landscape - 24matins.uk
Design Therapeutics Inc Stock Analysis and ForecastStock Rotation Strategies & Low Cost Stock Picks - earlytimes.in
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):